why choose us

Clinical Trials Search

Showing 19,470 of 132,963 result(s)
Phase II Trial of Lurbinectedin Combined With Avelumab as Switch Maintenance Firstline Therapy

Status: Completed

Condition: Metastatic Cancer

Interventions:

Avelumab 800 mg IV q 2 weeks (days 1,15, and 29 every 6 week cycle ) (premedication includes a H1 blocker, H2 blocker and Tylenol) Lurbinectedin 3.

Date: 2022-09-19

Safest Choice of Antihypertensive Regimen for Postpartum Hypertension

Status: Completed

Condition: Postpartum Complication

Interventions: Administration of oral nifedipine to control postpartum hypertension.

Date: 2022-09-19

A Study of Two Dose Levels of Vobramitamab Duocarmazine in Participants With Metastatic Castration Resistant Prostate Cancer

Status: ACTIVE_NOT_RECRUITING

Condition: Castration-Resistant Prostatic Cancer

Interventions: 2.0 mg;kg intravenous (IV) every 4 weeks

Date: 2022-09-19

Susceptibility-Guided Sequential Therapy for Helicobacter Pylori Infection

Status: Completed

Condition: Helicobacter Pylori Infection

Interventions: esomeprazole (20 mg, twice daily), clarithromycin (500 mg, twice daily), and amoxicillin (1.0 g, twice daily) for 14 days

Date: 2022-09-18

Bronchiolitis Recovery and the Use of High Efficiency Particulate Air (HEPA) Filters

Status: COMPLETED

Condition: Bronchiolitis

Interventions: To determine if use of a HEPA filtration unit home intervention reduces the respiratory symptom burden (symptom-free days; SFD) for 24 weeks compared

Date: 2022-09-17

Central Sensitization in Total Knee Arthroplasty Patients with Persistent Pain

Status: COMPLETED

Condition: Pain, Chronic Postsurgical

Interventions: Articular knee surface replacement

Date: 2022-09-17

SEARCH CAB LA Dynamic Choice HIV Prevention Study Extension

Status: COMPLETED

Condition: HIV

Interventions: CAB-LA will be one of the options for the Dynamic Choice Delivery intervention arm.
CAB-LA will be a choice for at-risk adults and adolescents we

Date: 2022-09-16

A Study to Evaluate RO7204239 in Participants With Facioscapulohumeral Muscular Dystrophy

Status: COMPLETED

Condition: Facioscapulohumeral Muscular Dystrophy (FSHD)

Interventions: DRUG: Placebo - Participants will receive subcutaneous (SC) placebo every 4 weeks (Q4W)
DRUG: RO7204239 - Participants will receive SC RO7204239

Date: 2022-09-16

Invasive PGT-A Embryo Selection Versus Non Invasive PGT-A Assisted Embryo Selection

Status: Completed

Condition: Infertility

Interventions: The basis of embryo selection for transfer: invasive PGT-A or after non-invasive PGT-A

Date: 2022-09-16

Improving Medication Adherence Using Family-focused and Literacy-sensitive Strategies

Status: Completed

Condition: Medication Adherence

Interventions: The FamLit (Family-focused and Literacy-sensitive strategy) is an interactive, multi-component intervention supported by the FamLit intervention Guide

Date: 2022-09-16